Regular alcohol use cut the effectiveness of a leading cancer immunotherapy by roughly half in mice and was linked to worse survival in patients who drank more than one drink a week, a study published November 17 in Science Signaling found.
The research, led by Kristen N. Gilley at the University of North Carolina at Chapel Hill, identifies a molecular mechanism: alcohol drives T cells to express a second “off-switch” receptor called TIGIT, blunting the very immune response that anti-PD-1 drugs such as pembrolizumab and nivolumab are designed to unleash. Blocking both PD-1 and TIGIT simultaneously restored tumor control in alcohol-exposed mice to levels seen in non-drinkers, Medical Xpress reported.
“This work is an initial resource toward establishing the risk of regular alcohol use on the efficacy of [immune checkpoint inhibition] and identifying the mechanisms that might be targeted for intervention,” Gilley and colleagues wrote in the paper.
The finding arrives as clinicians note that up to 76.4% of cancer patients continue to drink after diagnosis, despite standard advice to abstain. The UNC team gave mice ethanol equivalent to three to six human drinks daily for five weeks before implanting lung or bladder tumors, then treated them with anti-PD-1 antibodies. Tumor response dropped by approximately 50% and relapse rates climbed, news-medical.net reported.
How Alcohol Rewires the Tumor Microenvironment
Anti-PD-1 therapy works by blocking the PD-1 receptor on T cells, releasing a natural brake that tumors exploit to hide from the immune system. The UNC researchers discovered that chronic alcohol exposure adds a second brake: TIGIT (T cell immunoreceptor with Ig and ITIM domains).
In the mouse models, alcohol reduced the number of tumor-infiltrating CD4+ and CD8+ T cells — the primary soldiers that recognize and kill cancer cells.
It also skewed CD4+ T cells toward a T helper 17 (Th17) phenotype rather than the Th1 phenotype associated with effective anti-tumor immunity, and depleted tissue-resident memory T cells that provide long-term surveillance. Critically, alcohol increased the proportion of T cells expressing TIGIT and activated SREBP-mediated lipid signaling pathways inside those cells, the Science Signaling abstract shows.
When researchers added an anti-TIGIT antibody to the anti-PD-1 regimen, the combination “restored complete tumor response rates to almost the same level as in mice that had not consumed alcohol,” according to Medical Xpress. A SREBP inhibitor, betulin, offered partial rescue.
Weekly Alcohol Linked to Worse Immunotherapy Outcomes
- One drink a week mattered: In a retrospective review of patients treated at UNC Chapel Hill Cancer Hospital between 2014 and 2018, lung cancer patients who reported more than one drink per week saw reduced survival benefit from anti-PD-1 therapy.
- A second brake pedal: Alcohol doesn’t just weaken the immune system generally; it specifically upregulates TIGIT, a distinct checkpoint that anti-PD-1 drugs do not touch.
- Reversible in mice: Blocking TIGIT alongside PD-1 overcame the alcohol-induced resistance, suggesting a potential therapeutic strategy if validated in humans.
Human Data: Signals in Lung Cancer, Noise Elsewhere
The clinical arm of the study examined electronic health records from patients with skin, lung, bladder, or head and neck cancer receiving immune checkpoint inhibitors. The survival detriment was clearest in lung cancer. Effects were “less definitive” in melanoma, bladder, and head and neck cancers because alcohol-use reporting was too sparse in those cohorts, the study abstract states.
EurekAlert said that patients self-reporting eight or more drinks per week had poorer survival rates after starting checkpoint inhibition. However, the retrospective design cannot prove causation; patients who drink heavily may differ in nutrition, comorbidity burden, or treatment adherence.
Funding and Transparency
The work was conducted at the Bowles Center for Alcohol Studies, the Department of Pharmacology, and the Lineberger Comprehensive Cancer Center at the UNC School of Medicine. The paper lists 11 authors, including Jason Garness and Ali Khan. The Science Signaling publication page (DOI: 10.1126/scisignal.aef1375) lists the funding sources; readers should consult the full text for specific grant numbers and conflict-of-interest disclosures.
Anti-PD-1 Drugs Lack Alcohol Label Warnings
Anti-PD-1 antibodies — pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo) — are FDA-approved for more than a dozen indications across melanoma, non-small cell lung cancer, urothelial carcinoma, and head and neck squamous cell carcinoma. None of the current labels contain specific alcohol-related dosing modifications, though oncologists routinely counsel abstinence.
Anti-TIGIT agents such as tiragolumab (Roche/Genentech) and vibostolimab (Merck) have been tested in combination with PD-1/PD-L1 blockade in Phase II/III trials (e.g., SKYSCRAPER-01, SKYSCRAPER-02) with mixed results. The UNC data suggest patient alcohol history could be a stratification biomarker for future TIGIT combination trials.
| Model / Cohort | Alcohol Exposure | Primary Outcome | Rescue Strategy |
|---|---|---|---|
| Mouse (MB49 bladder) | Same regimen | Fewer CD8+ TILs; Th17 > Th1 shift; ↑ TIGIT+ T cells; ↑ SREBP signaling | Anti-TIGIT or betulin (SREBP inhibitor) |
| Human (UNC retrospective, n=various) | >1 drink/week (lung); ≥8 drinks/week (mixed cohort) | Reduced survival benefit on ICI (clearest in lung cancer) | Not tested |
Contraindications & When to Consult Your Oncologist
- Active immunotherapy patients: Discuss current alcohol intake with your care team; no universal “safe threshold” has been established for ICI efficacy.
- Liver dysfunction: Alcohol is contraindicated in patients with hepatitis, cirrhosis, or drug-induced liver injury from immunotherapy (immune-mediated hepatitis).
- Clinical trial enrollment: Alcohol use may affect eligibility or stratification in trials combining PD-1 and TIGIT inhibitors.
What Remains Unknown
The study authors call for prospective collection of precise alcohol quantities in cancer registries and electronic health records. “Incorporating patient’s alcohol use into cancer databases could shed light on its effect on other types of cancer therapies,” the team wrote. Whether lighter drinking — one to seven drinks weekly — impairs outcomes, and whether abstinence after treatment initiation reverses the TIGIT upregulation, are open questions.
The University of North Carolina at Chapel Hill, chartered in 1789 and enrolling students since 1795, is one of the oldest public universities in the United States and the only such institution to confer degrees in the eighteenth century.
It anchors one corner of North Carolina’s Research Triangle alongside North Carolina State University and Duke University. The National Science Foundation ranked it ninth nationally for research and development expenditures in 2023 at $1.5 billion, and its $5.7 billion endowment makes it the ninth-wealthiest public academic institution in the country as of 2024.
The next step, Gilley told the American Association for the Advancement of Science, is determining “how drinking affects ICIs” across cancer types with granular intake data.
References
- Gilley KN, Garness J, Khan A, et al. Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity. Science Signaling. 2026;19(912):eaf1375. doi:10.1126/scisignal.aef1375
- Medical Xpress. “Alcohol may weaken cancer immunotherapy, early research suggests.” Published November 2026.
- News-Medical.net. “Researchers reveal how regular alcohol use impairs the effectiveness of cancer immunotherapy.” Published November 18, 2026.
- EurekAlert. “New study may explain how drinking alcohol weakens the tumor-killing capabilities of cancer immunotherapy.” Published November 2026.